40 Correlation of relationship between infliximab and adalimumab trough and antibody levels with clinical response rates at completion of induction therapy
Gut, 2017 - search.proquest.com
Background Anti-TNFa therapies have improved response rates in inflammatory bowel
disease. However primary loss of response is problematic. Aim Aim of this study was to …
disease. However primary loss of response is problematic. Aim Aim of this study was to …
40 Correlation of relationship between infliximab and adalimumab trough and antibody levels with clinical response rates at completion of induction therapy
D Tighe, S Smith, A O'Connor, N Breslin, B Ryan… - 2017 - gut.bmj.com
Background Anti-TNFa therapies have improved response rates in inflammatory bowel
disease. However primary loss of response is problematic. Aim Aim of this study was to …
disease. However primary loss of response is problematic. Aim Aim of this study was to …